Payment overview · 2025
General Payments
$1,212.92
41 reported records · 10 companies
Healthcare provider profile · identity verified
Jose Aviles Munoz, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BAYAMON, PR · NPI 1144274333
Verified facts
What the public records show
CMS Open Payments records show Jose Aviles Munoz, MD received $1,212.92 in general payments during 2025 across 41 reported records.
Viatris Specialty LLC accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $255.14 | 21.0% | 9 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $219.85 | 18.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $198.41 | 16.4% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $190.59 | 15.7% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $143.96 | 11.9% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.21 | 9.2% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $25.00 | 2.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.08 | 2.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $24.08 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.60 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,212.92 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $255.14 | 9 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $219.85 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $166.52 | 7 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $143.96 | 6 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $143.96 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $134.78 | 5 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $57.04 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $54.17 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.18 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $29.45 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Janssen Pharmaceuticals, Inc | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
75 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 445 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 395 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 345 | 111 |
| Synthroid | Levothyroxine Sodium | 327 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 110 |
| Famotidine | Famotidine | 287 | 115 |
| Losartan Potassium | Losartan Potassium | 286 | 85 |
| Montelukast Sodium | Montelukast Sodium | 241 | 89 |
| Ezetimibe | Ezetimibe | 215 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 193 | 66 |
| Irbesartan | Irbesartan | 184 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 54 |
| Metformin Hcl | Metformin Hcl | 144 | 48 |
| Simvastatin | Simvastatin | 144 | 41 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 130 | 50 |
| Fenofibrate | Fenofibrate | 127 | 36 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 124 | 29 |
| Pregabalin | Pregabalin | 115 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 103 | 33 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 102 | 29 |
| Sertraline Hcl | Sertraline Hcl | 96 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 36 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 94 | 23 |
| Omeprazole | Omeprazole | 94 | 35 |
| Candesartan Cilexetil | Candesartan Cilexetil | 91 | 33 |
| Enalapril Maleate | Enalapril Maleate | 86 | 27 |
| Sucralfate | Sucralfate | 79 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 27 |
| Xarelto | Rivaroxaban | 75 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 18 |
| Farxiga | Dapagliflozin Propanediol | 68 | 20 |
| Carvedilol | Carvedilol | 66 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 17 |
| Alendronate Sodium | Alendronate Sodium | 63 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 63 | 17 |
| Buspirone Hcl | Buspirone Hcl | 63 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 24 |
| Tradjenta | Linagliptin | 61 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 60 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 33 |
| Trazodone Hcl | Trazodone Hcl | 60 | 26 |
| Clonazepam | Clonazepam | 59 | 13 |
| Torsemide | Torsemide | 59 | 21 |
| Finasteride | Finasteride | 58 | 16 |
| Nifedipine Er | Nifedipine | 57 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 56 | suppressed |
| Glimepiride | Glimepiride | 55 | 20 |
| Memantine Hcl | Memantine Hcl | 55 | 18 |
| Eliquis | Apixaban | 54 | 13 |
| Donepezil Hcl | Donepezil Hcl | 51 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 16 |
| Januvia | Sitagliptin Phosphate | 49 | 11 |
| Temazepam | Temazepam | 49 | suppressed |
| Jardiance | Empagliflozin | 48 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 19 |
| Azithromycin | Azithromycin | 47 | 42 |
| Latanoprost | Latanoprost | 47 | suppressed |
| Allopurinol | Allopurinol | 46 | 15 |
| Lisinopril | Lisinopril | 46 | 15 |
| Nabumetone | Nabumetone | 45 | 22 |
| Diclofenac Potassium | Diclofenac Potassium | 44 | 17 |
| Prednisone | Prednisone | 41 | 33 |
| Atrovent Hfa | Ipratropium Bromide | 40 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 40 | suppressed |
| Furosemide | Furosemide | 40 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 34 |
| Meloxicam | Meloxicam | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 33 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 32 | 21 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Folic Acid | Folic Acid | 29 | 11 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 21 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | 11 |
| Humalog | Insulin Lispro | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 25 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 23 | 20 |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Tadalafil | Tadalafil | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Etodolac Er | Etodolac | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Desonide | Desonide | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | 14 |
| Paroxetine Cr | Paroxetine Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Naproxen Sodium | Naproxen Sodium | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benzonatate | Benzonatate | 11 | 11 |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Estazolam | Estazolam | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Pregabalin Er | Pregabalin | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,212.92 · 41 records | Viatris Specialty LLC | AIRSUPRA, BREZTRI, CAPVAXIVE, DUPIXENT, EVENITY, GLASSIA, JARDIANCE, NUCALA, OFEV, REPATHA, TEZSPIRE, TRELEGY ELLIPTA, UPTRAVI, WINREVAIR, XYWAV, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error